Key stats
About Virtus LifeSci Biotech Products ETF
Home page
Inception date
Dec 17, 2014
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
Virtus Advisers LLC
Distributor
VP Distributors LLC
BBP offers a different approach to biotech investing by handpicking firms whose lead drugs are on its product stage or those firms that have attained FDA approval for their leading drug. Stocks must earn a majority of their revenue from the research and development and/or marketing and sale of novel drugs or other therapeutics used in the treatment of human diseases. The fund is offered by BioShares alongside launched a sister fund, BBC, which targets biotech firms in the clinical trial stage. The index is reconstituted on a semi-annual basis.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks98.73%
Health Technology98.73%
Bonds, Cash & Other1.27%
Cash1.27%
Stock breakdown by region
North America85.07%
Europe13.34%
Asia1.59%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
BBP top holdings are CRISPR Therapeutics AG and Ionis Pharmaceuticals, Inc., occupying 2.34% and 2.24% of the portfolio correspondingly.
BBP assets under management is 23.79 M USD. It's fallen 0.98% over the last month.
BBP fund flows account for 2.76 M USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
No, BBP doesn't pay dividends to its holders.
BBP shares are issued by Virtus Investment Partners, Inc. under the brand Virtus. The ETF was launched on Dec 17, 2014, and its management style is Passive.
BBP expense ratio is 0.79% meaning you'd have to pay 0.79% of your investment to help manage the fund.
BBP follows the LifeSci Biotechnology Products Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
BBP invests in stocks.
BBP price has fallen by −0.82% over the last month, and its yearly performance shows a 0.45% increase. See more dynamics on BBP price chart.
NAV returns, another gauge of an ETF dynamics, have risen by −2.29% over the last month, have fallen by −2.29% over the last month, showed a 11.89% increase in three-month performance and has increased by 0.77% in a year.
NAV returns, another gauge of an ETF dynamics, have risen by −2.29% over the last month, have fallen by −2.29% over the last month, showed a 11.89% increase in three-month performance and has increased by 0.77% in a year.
BBP trades at a premium (0.17%) meaning the ETF is trading at a higher price than the calculated NAV.